Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Endocrinology
Cardiology
Questions discussed in this category
Do you recommend continuing SGLT2 inhibitors in patients with diabetic kidney disease and congestive heart failure who have been taking the medication for several years and later develop end stage kidney disease?
3 Answers available
Should a toe-brachial index be obtained in lieu of resting ABI as an initial screen for PAD in high-risk patients such as those with longstanding diabetes or advanced age with stiffened vessels?
1 Answer available
Do you change management in patients that are taking bisphosphonates and develop atrial fibrillation?
1 Answer available
17261
13807
13518
Papers discussed in this category
The New England journal of medicine, 2015 Sep 17
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
The New England journal of medicine, 2020 Sep 24
Dapagliflozin in Patients with Chronic Kidney Disease.
Related Topics in Endocrinology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Genitourinary Cancers
Melanoma/Skin Cancer